Hormone Resistant Prostate Cancer Unknown Status Phase 2 Trials for Dasatinib (DB01254)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Unknown Status2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01685125Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment